It's really good that they are being so careful to make sure that the drug they'll be using is identical to the one that they'll market. Imagine if the drug were not exactly as they designed it -- it might not be as efficacious, and they might have to re-do the study. I suppose some on the other site will be whining about "delays" etc., but this caution is absolutely the smart way to proceed.

Note that they said they're using this study as a "gateway" to other applications like BIOFILMS. To me this was a hint that the implant device manufacturer is very much in the picture here. This would be a huge market and would help untold thousands of people to avoid post-surgical infection.